240 related articles for article (PubMed ID: 31364081)
21. Optimal Usage of Colistin: Are We Any Closer?
Pogue JM; Ortwine JK; Kaye KS
Clin Infect Dis; 2015 Dec; 61(12):1778-80. PubMed ID: 26354966
[No Abstract] [Full Text] [Related]
22. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
[TBL] [Abstract][Full Text] [Related]
23. Effects of polymyxin antibiotics on iodohippurate accumulation in rabbit renal cortical slices.
Milman N; Dahlager J
J Antibiot (Tokyo); 1978 Sep; 31(9):906-10. PubMed ID: 213415
[TBL] [Abstract][Full Text] [Related]
24. Interaction of Bacterial Phenazines with Colistimethate in Bronchial Epithelial Cells.
Mossine VV; Chance DL; Waters JK; Mawhinney TP
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784845
[TBL] [Abstract][Full Text] [Related]
25. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
[TBL] [Abstract][Full Text] [Related]
26. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
[TBL] [Abstract][Full Text] [Related]
28. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
29. Colistin: understanding and applying recent pharmacokinetic advances.
Ortwine JK; Kaye KS; Li J; Pogue JM
Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
[TBL] [Abstract][Full Text] [Related]
30. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
[TBL] [Abstract][Full Text] [Related]
31. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium.
Rogers MJ; Cohen J
Infection; 1986; 14(2):79-81. PubMed ID: 3011678
[TBL] [Abstract][Full Text] [Related]
33. Potential Toxicity of Polymyxins in Human Lung Epithelial Cells.
Ahmed MU; Velkov T; Lin YW; Yun B; Nowell CJ; Zhou F; Zhou QT; Chan K; Azad MAK; Li J
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416543
[TBL] [Abstract][Full Text] [Related]
34. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
35. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
[TBL] [Abstract][Full Text] [Related]
36. Adverse reactions associated with systemic polymyxin therapy.
Justo JA; Bosso JA
Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
[TBL] [Abstract][Full Text] [Related]
37. Polymyxin B, colistin, and sodium colistimethate.
Horton J; Pankey GA
Med Clin North Am; 1982 Jan; 66(1):135-42. PubMed ID: 6278236
[No Abstract] [Full Text] [Related]
38. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
[TBL] [Abstract][Full Text] [Related]
39. Colistin, mechanisms and prevalence of resistance.
Bialvaei AZ; Samadi Kafil H
Curr Med Res Opin; 2015 Apr; 31(4):707-21. PubMed ID: 25697677
[TBL] [Abstract][Full Text] [Related]
40. History, Chemistry and Antibacterial Spectrum.
Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
